Overview

Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC

Status:
Unknown status
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
A Controlled Clinical Study of Endostar/PD-1 Inhibitors Combined With chemotherapy(Carboplatin-Pemetrexed) as First-line Treatment for Advanced Non-squamous Cell Lung Cancer With Negative Driving Gene
Phase:
N/A
Details
Lead Sponsor:
Dong Wang
Treatments:
Endostar protein
Immune Checkpoint Inhibitors